Aandelen in “Farmaceutica”

Aandeel Datum Koers Evolutie
Even geduld...

Nieuws over “Farmaceutica”

16/06 · Bel20 opnieuw op pechstrook vredesrally · Tijd.be (€)

Bel20 opnieuw op pechstrook vredesrally

16/06 · Bel20 opnieuw op pechstrook vredesrally · Tijd.be (€)

De Europese beurzen zetten de vredesrally verder, maar de Bel20 kan weer niet volgen door een stevig verlies bij UCB. Kinepolis profiteert van een hoger koersdoel.

15/06 · Sanofi: Information concerning the total number of voting rights and shares – May 2026 · Persbericht

15/06 · IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2026 · Persbericht

15/06 · Bel20 doet niet mee aan vredesrally · Tijd.be (€)

Beleggers reageren opgetogen op de deal tussen de Verenigde Staten en Iran. Terwijl de Europese beurzen een vers record neerzetten, kleuren defensieve waarden de Bel20 rood. Vooral zwaargewicht UCB, d...

15/06 · Novo Nordisk A/S - share repurchase programme · Persbericht

15/06 · Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 · Persbericht

14/06 · Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 · Persbericht

14/06 · Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control · Persbericht

14/06 · Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL · Persbericht

13/06 · Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting · Persbericht

13/06 · New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma · Persbericht

13/06 · Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes · Persbericht

12/06 · Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) · Persbericht

12/06 · AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results · Persbericht

11/06 · Novo Nordisk A/S: IT Security incident at Novo Nordisk · Persbericht

11/06 · Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK · Persbericht

11/06 · AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease · Persbericht

11/06 · IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies · Persbericht

11/06 · Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint · Persbericht

10/06 · IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

Mijn selecties